Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Liver Int. 2011 Nov 22;32(4):665–674. doi: 10.1111/j.1478-3231.2011.02686.x

Table 3.

Risk of clinical liver disease progression by YKL-40 promoter polymorphism at rs4950928

All patients (n=462) With clinical progression (n=69) Without clinical progression (n=393) Hazard ratio (95% CI)* P-value
Homozygous major (CC) 292 (69.9%) 44 (66.7%) 248 (70.5%) 1 Ref 0.47
Heterozygous (CT) 119 (28.5%) 20 (30.3%) 99 (28.1%) 1.19 (0.75, 1.89)
Homozygous minor (TT) 7 (1.7%) 2 (3.0%) 5 (1.4%)
Missing rs4950928 44 3 41
*

HR calculated assuming an additive model and a continuous variable for genotype status.